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Abstract
Background: Iatrogenic hypothyroidism can develop after radioiodine-I131 (RAI)
treatment of hyperthyroid cats and can be diagnosed using the thyroid stimulating
hormone (TSH) stimulation test.
Objectives: To assess the effect of noncritical illness on TSH stimulation test results
in euthyroid and RAI-treated cats. To assess the correlation of low total-thyroxine
(tT4), low free-thyroxine (fT4), and high TSH concentrations with TSH stimulation
test results.
Animals: Thirty-three euthyroid adult cats and 118 client-owned cats previously
treated with RAI.
Methods: Total-thyroxine, fT4, and TSH were measured, and a TSH stimulation test
was performed in all cats. Euthyroid control cats were divided into apparently healthy
and noncritical illness groups. RAI-treated cats were divided into RAI-hypothyroid
(after-stimulation tT4 ≤ 1.5 μg/dL), RAI-euthyroid (after-stimulation tT4 ≥ 2.3 μg/dL
OR after-stimulation tT4 1.5-2.3 μg/dL and before : after tT4 ratio > 1.5), and RAI-
equivocal (after stimulation tT4 1.5-2.3 μg/dL and tT4 ratio < 1.5) groups.
Results: Noncritical illness did not significantly affect the tT4 following TSH stimula-
tion in euthyroid (P = .38) or RAI-treated cats (P = .54). There were 21 cats in the
RAI-equivocal group. Twenty-two (85%) RAI-hypothyroid cats (n = 26) and 10/71
(14%) of RAI-euthyroid cats had high TSH (≥0.3 ng/mL). Twenty-three (88%) RAI-
hypothyroid cats had low fT4 (<0.70 ng/dL). Of the 5 (7%) RAI-euthyroid cats with
low fT4, only one also had high TSH. Only 5/26 (19%) RAI-hypothyroid cats had tT4
below the laboratory reference interval (<0.78 μg/dL).
Abbreviations: BUN, blood urea nitrogen; CKD, chronic kidney disease; DVM, Doctor of Veterinary Medicine; ED, equilibrium dialysis; FIV, feline immunodeficiency virus; fT4, free-thyroxine;
RAI, radioiodine I131; rhTSH, recombinant human TSH; RI, reference interval; SBP, systolic blood pressure; T3, total tri-iodothyronine; TSH, thyroid stimulating hormone; tT4, total-thyroxine;
UPCR, urine protein-creatinine ratio; USG, urine-specific gravity.
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Conclusions and Clinical Relevance: The veterinary-specific chemiluminescent fT4
immunoassay and canine-specific TSH immunoassay can be used to aid in the diagno-
sis of iatrogenic hypothyroidism in cats.
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1 | INTRODUCTION
Biochemical evidence of iatrogenic hypothyroidism in radioiodine I131
(RAI) treated cats has been documented for decades. Historically, iatro-
genic hypothyroidism was not thought to be a clinically important prob-
lem in most cats, and treatment was not recommended unless clinical
signs consistent with hypothyroidism were present.1 Chronic kidney dis-
ease (CKD) is a common problem in the senior cat population,2,3 and
azotemia can be worsened by treatment of hyperthyroidism, because of
the decline in glomerular filtration rate that occurs after normalization of
thyroid hormone concentrations.4 Iatrogenic hypothyroidism in cats
treated with antithyroid medication and RAI increases the risk of azote-
mia and decreases survival time in azotemic-treated cats5,6 and therefore
the importance of diagnosis and treatment of iatrogenic hypothyroidism
is increasingly recognized.7
The diagnosis of iatrogenic hypothyroidism can be challenging
due to the effect of concurrent illness on serum free thyroxine (fT4)
and serum total thyroxine (tT4) concentrations,8,9 the poor sensitivity
and specificity of commercially available thyroid stimulating hormone
(TSH) assays, none of which are specific to cats,10 and the variability
in performance of various fT4 assay methodologies.11-13 Few studies
have looked at the sensitivity and specificity of the available thyroid
hormone analyses for the diagnosis of iatrogenic hypothyroidism in
cats.6,13
Traditionally tT4 has been used alone in cats to diagnose thyroid
disease; however, tT4 has poor sensitivity and specificity for the diag-
nosis of iatrogenic hypothyroidism in this species,6 especially when
laboratory reference intervals (RIs) are used. In humans and dogs,
combinations of fT4, tT4, and TSH are used to confirm a diagnosis of
hypothyroidism, or, if the diagnosis cannot be confirmed by measure-
ment of single thyroid hormones, thyroid scintigraphy, TSH stimula-
tion test or thyroid biopsy are performed.14
Thyroid scintigraphy is currently used as the reference test for
the diagnosis of hypothyroidism in RAI-treated cats.6,13 Increased
serum TSH concentrations (using canine-specific chemiluminescent
TSH immunoassay) are common in hypothyroid cats, whereas fT4
(using an equilibrium dialysis [ED] method) and tT4 concentrations are
within laboratory RI in 75% and 46% of hypothyroid cats, respec-
tively.6 Subclinical hypothyroidism, defined as cats with elevated
serum TSH concentration and fT4 or tT4 within the RI, is therefore
common in RAI-treated cats. This condition is clinically important due
to the potential harmful effects on renal function and consequent
decrease in survival time.6
The TSH stimulation test is considered a reliable reference test
for hypothyroidism in healthy dogs that are not on thyroid suppres-
sive medications (eg, glucocorticoids).15,16 Test criteria for the TSH
stimulation test in cats using recombinant human TSH (rhTSH) were
derived using 7 to 8 month old, specific pathogen free, research cats
which are not representative of the typically senior population of
client-owned cats with iatrogenic hypothyroidism.17 There are limited
data published looking at the response of mature adult, or senior cats
to the exogenous administration of rhTSH.18,19
In this prospective study, mature adult cats were recruited as a
control group and to assess the effect of noncritical illness on the
response of mature adult euthyroid cats to TSH administration. Radio-
iodine I131-treated cats presenting for wellness examinations were
recruited to receive a TSH stimulation test as a reference test of thy-
roid function, to test the correlation of low tT4, low fT4, and high
TSH with the results of the TSH stimulation test.
2 | METHODS
2.1 | Control cats
Mature adult cats were recruited from a local shelter and from study
staff, as control cats for the study. Cats on thyroid-suppressive medi-
cations (eg, prednisolone, budesonide, chlorambucil, tricyclic antide-
pressants, or fluoxetine) and cats diagnosed with hyperthyroidism
were excluded. Each control cat received a physical examination, sys-
tolic blood pressure (SBP) measurement, routine biochemistry and
hematology, urinalysis and urine protein : creatinine ratio (UPCR),
measurement of tT4, fT4 and TSH concentrations, and a TSH stimula-
tion test (see below). Weight at the time of the visit was compared to
historical shelter records or the patient's previous medical record.
Additional tests were performed as needed and available on the day,
such as tonometry, ECG, radiography, and cytology. Follow-up diag-
nostic testing (such as biopsy for histopathology) was performed by
the referring Doctor of Veterinary Medicine (DVM). Ethical approval
for the study was granted by the Douglas College Animal Care Com-
mittee (accredited by the Canadian Council on Animal Care), and all
procedures were performed after obtaining owner consent.
Dental disease was graded (dental score 1-4) subjectively
based on visual examination. Hypertension was defined as
SBP > 160 mm Hg measured on at least 2 occasions or on one
occasion with hypertensive retinal lesions. Renal azotemia
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(considered consistent with CKD) was defined as elevated serum
creatinine concentration (>2.5 mg/dL [the upper limit of the labo-
ratory (IDEXX Reference Laboratories Ltd, Delta, British Columbia,
Canada). RI derived from 173 healthy cats]) in conjunction with
poorly concentrated urine specific gravity (USG) (<1.035). Chronic
kidney disease (IRIS stage 2) was defined as a serum creatinine
concentration of 1.6 to 2.8 mg/dL plus USG < 1.035 on at least
two occasions plus at least one associated clinical sign: PU/PD,
hypertension, UPCR > 0.4, recurrent urinary tract infections, his-
tory of acute kidney injury, hypokalemia, hyperphosphatemia, non-
regenerative anemia, or weight loss > 5%.
Proteinuria was defined as UPCR > 0.4 without evidence of
pyuria or hematuria. Weight loss ≥ 5% in a cat with concurrent dis-
ease and >10% in cats without detectable concurrent disease was
considered a marker of clinically important concurrent disease in cats
fed ad libitum. Feline immunodeficiency virus positive cats were con-
sidered to have clinically important illness if they had evidence of
inflammatory disease (eg, gingivitis/stomatitis), anemia or leukopenia,
or weight loss (or a combination of signs).
Cats were divided into two groups: Group 0 (no clinically impor-
tant illness detected) and group 1 (noncritically ill) to analyze the
effect of illness on the response to exogenous TSH.
2.2 | Radioiodine I131-treated cats
A total of 949 hyperthyroid cats previously treated with RAI over
a 4-year period (2013-2016) at a single RAI treatment center were
evaluated for inclusion into this prospective study. Cats were
excluded if they were suffering from acute/severe illness (hospital-
ized cats, cats undergoing investigation of acute/severe clinical
signs, and cats that required emergency care on the day of their
examination for the study), if sedation would likely be required for
examination, if they were on a thyroid supplementation or iodine
restricted diet or on thyroid-suppressive medications (see above).
All excluded medications had a minimum withdrawal period of
6 weeks. Cats were included in the study at least 12 weeks after
RAI treatment.
Owners of eligible cats that met the inclusion criteria were offered
a wellness examination and laboratory testing. Data collected for each
cat included RAI treatment details, referring DVM medical record, clini-
cal signs questionnaire, physical examination findings (performed by
one of two DVMs), SBP measurement, routine biochemistry and hema-
tology, urinalysis and UPCR, thyroid hormone measurements (tT4, fT4,
TSH), and TSH stimulation test. Control cats were tested for feline leu-
kemia virus/feline immunodeficiency virus (FIV) status using an ELISA
method (IDEXX Laboratories SNAP Combo FeLV Ag/FIV Antibody
Immunoassay).
RAI cats were assessed for concurrent illness using the same
criteria as used for the control cats (see above) and divided into
two groups: no clinically important illness detected and non-
critically ill, to analyze the effect of illness on the thyroid hormone
results.
RAI cats were also divided into 3 groups (RAI-hypothyroid, RAI-
euthyroid, and RAI-equivocal groups) according to their TSH stimula-
tion test results.
2.3 | Systolic blood pressure measurement
A noninvasive Doppler technique was used to measure SBP after a
period of acclimatization, and using previously published methods.20
Average SBP was calculated from a minimum of 3 consecutive read-
ings (within 5 mm Hg). If average SBP was ≥160 mm Hg, indirect
fundoscopy was performed after applying one drop of tropicamide
1% to both eyes.
2.4 | Sample collection and handling
All baseline blood samples for thyroid hormone analysis and biochem-
istry were collected in the morning and placed into serum separator
tubes. After the initial blood collection, 0.05 mg of rhTSH was admin-
istered IV and a second blood sample was collected 6 hours later for
repeat measurement of tT4. Blood was allowed to clot for a minimum
of 20 minutes, centrifuged within 1 hour, stored at 4C to 6C. Urine
was collected by cystocentesis. All samples collected were analyzed
within 24 hours at a single local commercial laboratory.
2.5 | TSH stimulation test
Each 1.1 mg vial of rhTSH (THYROGEN thyrotropin alfa for injection,
Genzyme Corp. Thyrotropin alpha lyophilized powder for reconstitu-
tion) was reconstituted to a concentration of 1 mg/mL according to
the manufacturer instructions, divided into 22 individual doses
(0.05 mL) and stored at 4C to 6C for a maximum of 4 weeks as pre-
viously described.21 Dilution and aliquot assignment into individual
syringes was done by a compounding pharmacy under sterile
conditions.
2.6 | Biochemical assays
Serum tT4 was measured by a validated22 homogenous enzyme
immunoassay (DRI Thyroxine (T4) assay, Microgenics Corporation,
Freemont, California) on an automated biochemistry analyzer
(AU2700 Clinical Chemistry System, Beckman Coulter, Brea, Califor-
nia). Serum fT4 was measured using a semiautomated chemilumines-
cent immunoassay method for measuring fT4 with veterinary-specific
modification (VfT4) (IMMULITE 2000 Veterinary Free T4 (Catalogue
no. L2KVF42), Siemens Healthcare Diagnostics Products Ltd. Glyn
Rhonwy, Llanberis, Gwynedd LL55 4EL, United Kingdom). TSH in cats
was measured using a canine TSH (IMMULITE 2000 Canine TSH
(Catalogue no. L2KKT6), Siemens Healthcare Diagnostics Products
Ltd. Glyn Rhonwy, Llanberis, Gwynedd LL55 4EL, United Kingdom)
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assay previously validated with feline samples.23 VfT4 and TSH were
run on a commercial immunoassay system (Immulite 2000 XPi; Sie-
mens Medical Solutions. Flanders, New Jersey).
Renal function was assessed by measurement of serum creatinine
concentrations (by Jaffe reaction), blood urea nitrogen (BUN) concen-
trations, USG, UPCR, and SBP.
2.7 | Data presentation and statistical analysis
All statistical analyses were performed using proprietary statistical
software (IBM SPSS Statistics 24). All analyses used nonparametric
tests due to small group sizes and inconsistent normal distribution of
data. All data are presented as median (interquartile range). Statistical
significance was defined as P < .05. The results of the TSH stimulation
test are reported as the serum tT4 concentration 6 hours after IV TSH
administration (after-stimulation tT4) and as the ratio of the tT4 con-
centration before and after TSH administration (T4-ratio).
2.7.1 | Control cats
Using the control group data, a RI for after-stimulation tT4 and tT4 ratio
was generated using the robust method with Box-Cox transformation
of the data by proprietary software.24 The after-stimulation-tT4 and
tT4 ratio were compared between the two control cat groups using the
Mann-Whitney U test with a P value <.05 used to indicate significance.
2.7.2 | RAI-treated cats
Continuous variables were compared between groups by the Kruskal-
Wallis test, followed by Dunn's multiple comparisons test. Hormone
values below the limit of detection, or above the upper threshold,
of the assay were assigned arbitrary values for the analysis as follows:
TSH <0.03 = 0.02 ng/mL, TSH >12 = 12 ng/mL, fT4 < 0.29 ng/
dL = 0.27 ng/dL. All categorical variables were compared using the
Pearson Chi-squared test, including an assessment of the proportion
of cats with and without illness, between the three thyroid function
groups.
3 | RESULTS
3.1 | Control cats
A total of 36 control cats were recruited, 12 from private homes and
24 group shelter-housed. Three cats were diagnosed with hyperthy-
roidism and excluded, therefore 33 cats were included in study. Many
shelter cats were of unknown age but all were estimated to be at least
6 years old. Of the 21 cats whose age was known, the median age
was 10 years old.7-14
The majority of control cats included in the study were Domestic
short- or long-haired cats (n = 31) and two purebred cats were
included (Persian [n = 1], Peterbald [n = 1]). All cats were neutered
with 17 female cats and 16 male cats included in the study. The
median weight of control group cats (4.9 [3.7-6.1] kg) was not signifi-
cantly different from the RAI-treated cats (5.0 [4.1-6.0] kg: P = .48;
Table 1).
Medications administered at the time of the TSH stimulation test
included: preventative flea treatments (selamectin (Revolution Zoetis
Canada 16740 Trans-Canada Hwy, Kirkland, Quebec H9H 4J4,
Canada) n = 4, imidacloprid/pyriproxyfen (Advantage II Bayer Inc.,
2920 Matheson Boulevard East. Mississauga, Ontario Canada L4W
5R6) n = 1), benazepril (Fortekor Elanco 150 Research Lane, Suite
120 Guelph, ON N1G 4T2) and ranitidine (Zantac® Sanofi 2905 Place
Louis-R.-Renaud, Laval, QC H7V 0A3, Canada) (n = 1), potentiated
amoxicillin (Clavaseptin Vetoquinol N.-A inc 2000, chemin Georges,
TABLE 1 Thyroid hormone
concentrations, response to TSH
administration and selected biochemical
and clinical measurements, in mature
adult control cats divided into two
groups: apparently healthy (group 0) and
noncritically ill (group 1)
Variable Control group 0 Control group 1
Weight (kg) 5.25 [3.8-6.3] 4.55 [3.52-5.63] P = .15
SBP (mm Hg) 120 [108-132] 118 [110-147] P = .88
Heart rate (bpm) 216 [180-228] 168 [158-199] P = .003
Creatinine (mg/dL) 1.28 [1.18-1.81] 1.37 [1.24-1.67] P = .4
BUN (mg/dL) 28 [21.8-33.3] 25.2 [20.4-32.2] P = .71
tT4 (μg/dL) 2.0 [1.72-2.17] 2.07 [1.61-2.34] P = .99
fT4 (ng/dL) 1.2 [1.1-1.6] 1.4 [1.0-1.9] P = .9
TSH (ng/mL) 0.04 [<0.03-0.07] 0.03 [<0.03-0.07] P = .71
After-stimulation tT4
(μg/dL)
5.2 [4.6-5.9] 4.7 [3.4-5.7] P = .38
T4 ratio 2.4 [2.1-2.9] 2.3 [1.9-2.8] P = .46
Note: Data are presented as median [interquartile range].
Abbreviations: BUN, blood urea nitrogen; SBP, systolic blood pressure; TSH, thyroid stimulating
hormone.
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Lavaltrie, Québec J5T 3S5, Canada) (n = 1), insulin (Lantus® Sanofi
2905 Place Louis-R.-Renaud, Laval, QC H7V 0A3) (n = 1).
Control cats in group 0 (no clinically important illness: n = 15)
included cats with mild to moderate dental calculus or isolated sus-
pect feline odontoclastic resorptive lesions (n = 10), cats with a grade 2
to 3 heart murmur but no other evidence of heart disease (n = 2), and
an apparently healthy FIV positive cat (n = 1).
Control cats in group 1 (noncritically ill: n = 18) included a mildly
jaundiced cat with early evidence of hepatic lipidosis (hepatic lipidosis
later confirmed by biopsy), FIV positive cats with moderate-severe
gingivitis/stomatitis, weight loss, or both (n = 3), a cat with 3rd degree
heart block, severe hypertension (SBP > 200 mm Hg) and CKD (IRIS
stage 2), a treated but poorly controlled diabetic cat with a heart mur-
mur, cats with IRIS stage 2 CKD (n = 2), a nonpyrexic cat with evi-
dence of marked systemic inflammation/infection including bands and
toxic neutrophils, cats with grade 4 dental disease and evidence of
oral pain (n = 2) and cats with multiple clinically important markers of
illness such as moderate hypokalemia (K+ 3.0-3.5 mmoL/L; n = 2),
moderate nonregenerative anemia (PCV = 20%: n = 1), hypo-
albuminemia (albumin = 22 g/L: n = 1), systolic hypertension (n = 3),
and proteinuria (n = 1). Weight loss was recorded in 12/18 of the cats
in this group, 3 cats had stable or increased weight, and 3 cats had no
historical weight data available.
3.2 | TSH stimulation test results in control
group cats
The T4 ratio (P = .46) and after-stimulation-tT4 (P = .38) were not sig-
nificantly different between the two control cat groups (Table 1).
The control cat data were used to derive a RI minimum after-
stimulation tT4 concentration (2.3 μg/dL) and a reference minimum
tT4 ratio (1.5) after rhTSH administration. These values were used to
determine the euthyroid cut-off points for the RAI-treated cats.
3.3 | TSH stimulation test criteria for RAI-
treated cats
After administration of rhTSH, the control group cats had a higher
median after-stimulation tT4 (5.0 [3.9-5.8] μg/dL) and T4ratio (2.41
[2.09-2.82] μg/dL) than the RAI-treated cats (Figures 1 and 2: P < .001).
The RAI-treated cats were divided into three groups based on the
following criteria: RAI-euthyroid group (n = 71); after-stimulation
tT4 ≥ 2.3 μg/dL or after-stimulation tT4 1.5 to 2.3 μg/dL and
before : after tT4 ratio ≥ 1.5, RAI-equivocal group (n−21); after-
stimulation tT4 1.5 to 2.3 μg/dL and tT4 ratio < 1.5, RAI-hypothyroid
group (n = 26); after-stimulation tT4 ≤ 1.5 μg/dL.
3.4 | RAI-treated cats
A total of 118 RAI-treated cats were recruited including 106 domestic
short- or long-haired cats and 12 purebred cats: all cats were neutered
(female n = 64, male n = 54). Twenty cats were receiving medication
F IGURE 1 Boxplot demonstrating the concentration of total
thyroxine (tT4), 6 hours after intravenous rhTSH administration, in
4 groups of cats (after-stimulation tT4). The 4 groups are RAI-
Euthyroid (RAI-treated cats with good response to rhTSH
administration n = 71), RAI-Equivocal (RAI-treated cats with poor
response to rhTSH administration n = 21), RAI-Hypothyroid (RAI-
treated cats with low or low normal tT4 concentration and no, or
inadequate, response to rhTSH administration n = 26) and Controls
(euthyroid mature adult cats n = 33). The box in the boxplot
represents the interquartile (IQ) range, the horizontal bar
represents the median value. The whiskers represent the data
outside the IQ range but excluding individual values >1.5 box-
lengths from the upper and lower edges of the box. Outliers >1.5
box-lengths from the edges of the box are represented by stars.
RAI, radioiodine-I131; rhTSH, recombinant human thyroid
stimulating hormone
F IGURE 2 Boxplot demonstrating the ratio of total thyroxine
concentration (tT4 ratio), before and 6 hours after intravenous rhTSH
administration, in 4 groups of cats. Control cats had a significantly
higher (P < .001) T4 ratio compared to the radioiodine treated cats.
The groups are as described in Figure 1 legend. See Figure 1 for
boxplot key. rhTSH, recombinant human thyroid stimulating hormone
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at the time of the TSH stimulation test including potassium supple-
ments (n = 6), insulin (n = 2), cyclosporine (Lantus Sanofi 2905 Place
Louis-R.-Renaud, Laval, QC H7V 0A3, Canada) (n = 1), benazepril
(n = 2), maropitant citrate (Atopica Elanco 150 Research Lane, Suite
120 Guelph, ON N1G 4T2, Canada) (n = 1) famotidine (Cerenia Zoetis
Canada 16740 Trans-Canada Hwy, Kirkland, Quebec H9H 4J4) (n = 2)
and the following generic or compounded drugs: amlodipine (n = 3),
buprenorphine (n = 1), gabapentin (n = 2), atenolol (n = 1), ursodiol
(n = 3), and amoxicillin (n = 1). Radioiodine I131-treated cats were older
(14 [12–15] years) than the control cats (9 [7.0-10.5] years: P < .001)
(Table 2).
Fifty-one of the 118 RAI cats were identified as having noncritical
illness. This included azotemia (n = 25), nonazotemic IRIS grade 2
CKD (n = 15), grade 4 dental disease (n = 6, of which 4 also had CKD),
untreated hypertension (n = 9, of which 4 also had CKD) or other con-
current disease/weight loss (diabetes mellitus n = 2, gastrointestinal
disease n = 2, hepatitis n = 1, heart disease n = 2).
There was no significant difference in the proportion of cats with
and without illness between the hypothyroid and nonhypothyroid
groups (P = .34) and no significant difference when the effect of ill-
ness on after-stimulation tT4 was compared within the 3 (RAI-euthy-
roid, RAI-intermediate, and RAI-hypothyroid) groups (P = .54).
3.5 | Thyroid hormone concentrations
The median TSH concentration in control cats was significantly lower
(0.04 [<0.03-0.07] ng/mL) than the median TSH in the RAI-euthyroid
TABLE 2 RAI treatment variables and select clinical and biochemical variables in mature adult euthyroid cats, and in RAI-treated cats divided
into three groups according to response to TSH administration (see Section 2)
Variable Control group RAI-euthyroid RAI-equivocal RAI-hypothyroid
Number (n) 33 71 21 26
Age (y) 9 [7.0-10.5]1,2,3 13 [11-15]1,4 14 [11.5-15.5]2 15 [14-16]3,4 1,2,3P < .001
4P = .01
Weight (kg) 4.9 [3.7-6.0] 5.3 [4.4-6.5]1 4.3 [3.9-5.4] 4.2 [3.8-5.7]1 1P = .009
SBP (mm Hg) 119 [108-134] 1,2 133 [121-149]1 140 [115-150] 150 [123-166]2 1P = .005
2P = .02
Heart rate (bpm) 192 [161-216] 180 [168-192] 180 [174-192] 171 [154-192]
Creatinine (mg/dL) 1.36 [1.20-1.76]1,2,3 1.85 [1.49-2.33]1,4 1.76 [1.39-1.96]2,5 2.3 [1.83-2.92]3,4,5 1,3P < .001
2P = .02
4,5P = .003
BUN (mg/dL) 26.6 [21.6-32.8]1 29.1 [26.6-35.3]2 31.1 [20.7-44.2] 33.3 [28.6-45.4]1, 2 1,P = .001
2P = .02
RAI dose (miCu) NA 3.5 [2.5-4.1] 3.2 [2.35-4.2] 3.65 [2.65-4.38]
Before RAI tT4 (μg/dL) NA 8.9 [6.1-12.4] 9.5 [5.6-13.3] 11.1 [5.9-13.2]
Time to T0 (d) NA 427 [298-784] 274 [212-546] 435 [219-563]
Note: Data are presented as median [interquartile range]. Values with the same superscript numbers are significantly different to one another.
Abbreviations: BUN, blood urea nitrogen; RAI, radioiodine I131; SBP, systolic blood pressure; TSH, thyroid stimulating hormone.
TABLE 3 Thyroid hormones at baseline and after administration of rhTSH in control cats and in RAI-treated cats divided into three groups
according to response to TSH administration (see Section 2)
Variable Control group RAI-euthyroid RAI-equivocal RAI-hypothyroid
tT4 (μg/dL) 2.0 [1.7-2.3] 1,2 1.8 [1.6-2.1] 3,4 1.6 [1.4-1.7]1,5 1.0 [0.8-1.3]2 1,2,3,4,5P < .001
fT4 (ng/dL) 1.3 [1.1-1.6] 1,2,3 1.1 [0.9-1.4] 1,4,5 0.9 [0.6-1.1] 2,4,6 0.35 [0.27-0.56] 3,5,6 1P = .04 2,3,4,5,6P < .001




5.0 [3.9-5.8] 1,2,3 3.4 [2.8-4.2] 1,4,5 1.9 [1.7-2.1] 2,4,6 1.2 [0.9-1.5]3,5,6 1,2,3,4,5,6P < .001
T4 ratio 2.41 [2.09-2.82]1,2,3 1.85 [1.56-2.13] 1,4,5 1.30 [1.16-1.38]2,4,6 1.15 [1.04-1.23] 3,5,6 1,2,3,4,5P < .001
6P = .003
Note: Data are presented as median [interquartile range]. Values with the same superscript numbers are significantly different to one another.
Abbreviations: RAI, radioiodine-I131; rhTSH, recombinant human thyroid stimulating hormone; TSH, thyroid stimulating hormone.
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group (0.13 [0.07-0.24] ng/mL: P < .001). Control cats also had a sig-
nificantly higher fT4 (1.3 [1.1-1.6] ng/dL) compared to the RAI-
euthyroid group (1.1 [0.9-1.4] ng/dL: P = .04), however, no difference
in tT4 concentrations was observed (Table 3).
RAI-hypothyroid cats had significantly higher TSH (P < .001),
lower tT4 (P < .001), and lower fT4 (P < .001) than the RAI-euthyroid
or RAI-equivocal groups (Table 3).
Only 5/26 (19%) RAI-hypothyroid cats in our study had a tT4
concentration below the laboratory RI (<0.78 μg/dL; Figure 3); how-
ever, low fT4 (<0.70 ng/dL) was detected in 88% of the RAI-
hypothyroid cats (Table 4). TSH was high in (85%) of RAI-hypothyroid
cats but 14% of the RAI-euthyroid and 57% of the RAI-equivocal
groups also had high TSH. Of the 5 RAI-euthyroid cats with low fT4,
only 1/5 had a high TSH (0.32 ng/mL, Figure 4).
3.6 | Relationship between thyroid status and
radioiodine treatment
The median [IQ range] dose of RAI received by the RAI-treated cats
was 3.5 [2.5-4.1] mCi (Table 2) and the majority of cats were included
in the study at least 12 months (422.5 [269-697] days) after RAI treat-
ment. In cases where two RAI treatments were given, the second dose
is included in the data set and the date of the second treatment used
to calculate time after treatment. The median tT4 concentration at
diagnosis (before RAI treatment) in the RAI-treated cats was 9.1
(6.1-12.7) μg/dL. There were no significant differences in the radio-
iodine dose received (P = .41), highest before-treatment tT4 (P = .83),
or time interval between RAI treatment and TSH stimulation test
(P = .22), between the three groups (Table 2).
F IGURE 3 Scatterplot of baseline total thyroxine and
endogenous TSH concentrations in RAI-treated cats divided into
three groups based on response to exogenous rhTSH (groups
described in Figure 1.). The horizontal dotted line represents the
lower end of the laboratory reference range for tT4 and the vertical
dotted line represents a previously published6 reference cut-off for
TSH in cats (0.3 ng/mL). The gray box depicts the diagnostic area for
hypothyroidism if both tT4 and TSH concentrations were to be used
for diagnosis, and using the published reference cut-offs. RAI,
radioiodine-I131; rhTSH, recombinant human thyroid stimulating
hormone; TSH, thyroid stimulating hormone
TABLE 4 Proportion (number) of
RAI-treated cats with fT4, and tT4 below
the laboratory reference range, and
TSH > 0.3 ng/mL when divided into RAI-
hypothyroid, RAI-equivocal, and RAI-
euthyroid groups using the TSH
stimulation test results
Thyroid hormone RAI-hypothyroid % (n) RAI-equivocal % (n) RAI-euthyroid % (n)
Number of cats 26 21 71
fT4 < 0.70 ng/dL 88% (23) 33% (7) 7% (5)
tT4 < 0.78 μg/dL 19% (5) 0% (0) 1.4% (1)
TSH ≥ 0.3 ng/mL 85% (22) 57% (12) 14% (10)
Abbreviations: RAI, radioiodine-I131; TSH, thyroid stimulating hormone.
F IGURE 4 Scatterplot of baseline free thyroxine and endogenous
TSH concentrations in RAI-treated cats divided into three groups
based on response to exogenous rhTSH (groups described in
Figure 1). Control cats are included for comparison. The horizontal
dotted line represents the lower end of the laboratory reference
range for fT4 and the vertical dotted line represents a previously
published6 reference cut-off for TSH in cats. The gray box depicts the
diagnostic area for hypothyroidism if both fT4 and TSH
concentrations were to be used for diagnosis, and using published
reference cut-offs. RAI, radioiodine-I131; rhTSH, recombinant human
thyroid stimulating hormone; TSH, thyroid stimulating hormone
WAKELING ET AL. 2271
3.7 | Relationship between thyroid status and
renal function
RAI-hypothyroid cats were significantly more likely to be azotemic (39%)
than the RAI-euthyroid (14%) and RAI-equivocal (15%) groups (P = .03)
and had a higher serum creatinine concentration (2.30 [1.83-2.93] mg/dL)
than the RAI-equivocal (1.76 [1.39-1.96] mg/dL]; P = .003) or RAI-euthy-
roid (1.85 [1.49-2.33] mg/dL; Table 2; P = .003) cats. RAI-hypothyroid
cats also had a higher BUN (33.3 [28.6-45.4] mg/dL) than the RAI-
euthyroid (29.1 [26.6-35.3] mg/dL) cats (P = .02). There was no signifi-
cant difference in USG or UPCR between the three groups.
3.8 | Relationship between thyroid status and SBP
Cats receiving amlodipine treatment at the time of examination were
not included in the analysis of blood pressure (n = 4; all in the RAI-
euthyroid group). There was no significant difference in SBP between
the three RAI-treated groups; however, SBP was higher in the RAI-
hypothyroid group compared to the control group (P = .02).
4 | DISCUSSION
The principal findings of the study are that noncritical illness does not
appear to affect the results of the TSH stimulation test in mature adult
cats, and that the response to TSH stimulation is typically suppressed
in RAI-treated cats compared to controls. The proportion of RAI-
hypothyroid cats with a low fT4 concentration (88%) and a high TSH
concentration (85%) was high, but a high proportion of RAI-equivocal
(57%) and RAI-euthyroid (14%) also had high TSH. Therefore, use of
TSH alone as a diagnostic test for hypothyroidism could lead to a high
risk of false positive diagnoses. Conversely, if a clinician were to rely
solely on a tT4 concentration below the RI to identify possible hypo-
thyroidism in RAI-treated cats, there is a high risk of a false negative
diagnosis, that is, a high proportion (81%) of hypothyroid cats would
be missed.
Two recent studies of RAI-treated cats have used scintigraphy as the
reference test to determine thyroid function. In the first study of iatro-
genic hypothyroidism in RAI-treated cats with CKD,6 TSH had a high sen-
sitivity and specificity, and fT4 had a low sensitivity, for the diagnosis of
iatrogenic hypothyroidism. In the second study,13 which did not identify
any hypothyroid cats on scintigraphy, 27% of euthyroid cats had a high
TSH, and 41% euthyroid cats had a low fT4 (using the same non-ED
assay). In contrast, 7% of RAI-euthyroid cats in our study had low fT4,
and 14% had high TSH (furthermore RAI-equivocal cats had higher pro-
portions with low fT4/high TSH).
There could be a number of reasons for the difference
between the findings of our study and previous studies. The TSH
stimulation test, scintigraphy, and histopathology have all been
used as reference tests for the diagnosis of primary hypothyroid-
ism in dogs. One dog study concluded that scintigraphy is more
reliable than the TSH stimulation test to distinguish nonthyroidal
illness from hypothyroidism, in dogs with a low tT4.14 In addition,
iodine trapping can be decreased or asymmetrical in dogs with var-
ious nonthyroidal illnesses, and technetium uptake by the thyroid
can be affected by some drugs, amyloidosis, high iodine content in
the diet and active thyroiditis.25,26 There are no similar studies
comparing the reliability of these reference tests in cats. Hypothy-
roidism in dogs has a different etiopathogenesis and pat-
hodynamics compared with iatrogenic hypothyroidism in cats,
therefore extrapolation of the findings of dog studies to cats might
not be valid. One of the previous studies of iatrogenic hypothy-
roidism in RAI-treated cats only included cats with CKD, whereas
our study recruited any RAI-treated cat that met our inclusion
criteria, regardless of renal function. Since CKD can change the
dynamics of iodine metabolism and excretion,27 it is possible that
technetium uptake could be altered in cats with CKD compared to
cats with normal renal function, therefore affecting the reliability
of thyroid scintigraphy as a diagnostic test for iatrogenic hypothy-
roidism in cats with CKD.
Our study used the TSH stimulation test as a reference test of
thyroid function in RAI-treated cats. The cut-points used to interpret
the TSH stimulation test results in our study were based on RIs
derived from a group of mature euthyroid adult control cats. The TSH
stimulation test is a test of thyroid reserve and it is apparent from our
data set that the majority of RAI-treated cats had a decreased thyroid
reserve compared to untreated euthyroid cats. As with all endocrine
diseases, it is hard to place defined cut-points into a system where
many individuals fall into a gray zone between clearly normal and
clearly abnormal, and we therefore included a 3rd group of cats with
“equivocal” function. This approach has been used previously, for
example, in studies of thyroid function in dogs15 and in a recent study
of diagnostic tests for pancreatitis in cats.28 The inclusion of this third
group of cats meant that a calculation of sensitivity and specificity for
thyroid hormones as diagnostic tests for hypothyroidism could not be
performed in our study.
Our study did not find a difference in response to TSH
between control cats with noncritical illness and relatively healthy
controls, or between the different groups of RAI-treated cats,
which concurs with the findings of a previous study.18 As noted
above, sick euthyroidism can lead to a decreased response to
exogenous TSH administration, with the potential for a false posi-
tive diagnosis of hypothyroidism.14,29 It was therefore important
for us to determine if the suppressed response to TSH in our study
was due to concurrent illness, before we attributed the results to a
depressed thyroid reserve. There were a wide variety of different
types of concurrent illnesses in our study cats, which is common in
senior cat populations. Although we were able to apply objective
measures of illness in some cases (eg, blood pressure and weight
loss), in some cases the categorization of cats as “ill” and “not ill”
somewhat subjective (eg, the assessment of dental disease). It is
important to note that our recruitment strategy resulted in the
inclusion of a relatively healthy population of cats and none of our
control cats had subnormal tT4 despite their illnesses. Therefore,
our conclusion that noncritical illness had no effect on the results
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of the TSH stimulation test cannot be extrapolated to sick euthy-
roid cats with subnormal tT4 concentrations.
High TSH (>0.3 ng/mL) has a 98.5% specificity and a 100%
sensitivity for the diagnosis of hypothyroidism6 whereas in our
study, 85% of RAI-hypothyroid cats had high TSH (suggesting a
lower sensitivity) and 57% of the RAI-equivocal cats had high TSH
(suggesting a lower specificity). Our results also concur with
another study in which the specificity of high TSH for hypothy-
roidism was 73%.13 This difference in the sensitivity and specific-
ity of TSH is of particular note because the same canine TSH
assay was used in all three studies. It could be speculated that
these differences could be due to the criteria we used to define
hypothyroidism and euthyroidism. For example, it is possible that
some RAI-equivocal and even RAI-euthyroid cats in our study
might have been categorized as hypothyroid using scintigraphy. In
order to be categorized as euthyroid for our study, RAI-treated
cats did not have to meet a minimum 50% increase in tT4 after-
TSH administration, if their after-stimulation tT4 was >2.3 μg/dL.
I131RAI-euthyroid cats in our study had a higher median TSH than
the control group and 10/71 cats in the RAI-euthyroid group had
a high TSH (≥0.3 ng/mL); however, only 3 of the 10 euthyroid cats
with high TSH and after-stimulation tT4 > 2.3 μg/dL had a tT4
ratio < 1.5.
Previous studies have shown that pituitary secretion of TSH
takes 1 to 3 months to recover after resolution of hyperthyroid-
ism5; however all cats in our study were tested >3 months after
RAI with a median time of 422 days between RAI and the TSH
stimulation test. In addition, there was no difference in time inter-
val between RAI and TSH stimulation test in the RAI-euthyroid,
RAI-equivocal and RAI-hypothyroid cats. Therefore, the timing of
the TSH stimulation test in relation to RAI treatment is unlikely to
have influenced the categorization of the RAI cats into different
thyroid function groups.
The non-ED veterinary free T4 assay used in this study corre-
lated better with a diagnosis of hypothyroidism compared to the
ED fT4 assay used in the Peterson study6. In the Peterson study,
low fT4 (below the laboratory RI) had a sensitivity and specificity
of 25% and 98% respectively, whereas in our study, 88% of RAI-
hypothyroid cats had a fT4 below the laboratory RI. In a separate
study, which used the same method and fT4 cut-point (0.7 ng/dL)
for diagnosis of hypothyroidism as our study, 41% of euthyroid
cats had a fT4 below the laboratory RI, whereas in our study 7% of
RAI-euthyroid and 33% of RAI-equivocal had a low fT4.13 These
data suggest that the non-ED veterinary fT4 assay used in our
study (and the study by Stameleer et al) gives fewer false negative
results (is more sensitive) but more false positive results (is less
specific) for iatrogenic hypothyroidism in cats than the assay used
in the Peterson study. This could reflect differences in assay cali-
bration or assay sensitivity that leads to lower measured fT4 con-
centrations with our assay. This supposition is supported by our
data set in which >25% of RAI-hypothyroid cats had a fT4 below
the limit of detection, whereas most of these cats had detectable
tT4 concentrations. Although a high correlation between the non-
ED fT4 assay used in our study and tT4 has been reported,13 the
aforementioned study did not perform a Bland Altman analysis to
test for systematic differences between these variables. Therefore,
it is possible that the non-ED fT4 assay used in both the aforemen-
tioned study and our study consistently underestimates the fT4,
which could account for the lower false negative and higher false
positive rate observed in our study compared to the Peterson
study. In addition, only one of the 71 RAI-euthyroid cats had both
a low fT4 (0.55 ng/dL) and a high TSH (0.32 ng/mL), which sug-
gests that combining fT4 and TSH measurements might decrease
the risk of a false positive hypothyroidism diagnosis compared to
using fT4 or TSH alone.
The non-ED fT4 assay is a veterinary specific chemilumines-
cent assay but does not use an ED step to isolate the free
(unbound) thyroxine from the protein-bound fraction. A number of
studies have looked at the reliability of fT4 assays11,12 for the
diagnosis of hypothyroidism and hyperthyroidism, using both
radio-assay and chemiluminescent methods, with and without ED,
and most studies have concluded that ED methods are superior to
non-ED methods. Free T4 could not be determined by ED in our
study due to financial constraints, therefore we could only evalu-
ate the performance of the commercial veterinary chemilumines-
cent free T4 assay available at our local reference laboratory. Our
results suggest that this fT4 assay (particularly in combination with
TSH) might be a reliable test for iatrogenic hypothyroidism in cats,
when TSH stimulation testing is used as the reference test; how-
ever, additional validation studies are required to confirm analyti-
cal precision and reproducibility.
As with previous studies in cats,6,18 baseline tT4 concentrations
were within reference range in the majority of cats diagnosed with iat-
rogenic hypothyroidism. This reinforces the need to measure TSH and
fT4 when assessing RAI-treated cats for biochemical evidence of hypo-
thyroidism, and veterinarians need to be especially vigilant in RAI-
treated cats with low-normal tT4 concentrations (0.78-1.5 μg/dL). In
this study, none of the RAI-equivocal, and only one RAI-euthyroid cat
had a tT4 below the RI (<0.78 μg/dL), likely due to the fact that our
study design and inclusion/exclusion criteria excluded cats likely to
have severe nonthyroidal illness. We expect that the specificity of
low tT4 for iatrogenic hypothyroidism would be lower in cats with
severe nonthyroidal illness, and further studies would be required to
confirm this.
In our study, baseline tT4 was lower and response to rhTSH
administration was decreased in the euthyroid control cats com-
pared to previous studies.17-19 It is possible that these differences
in baseline T4 and response to exogenous TSH could be due to the
much younger age of the cats in the previous studies (7-8 months
and 2 years, respectively), compared with the median age of
9 [7-10.5] years old of the control cats in our study. There is con-
flicting evidence that tT4 concentrations change with age in cats,
with an effect of age being reported in some studies30 but not in
others.9
In our prospective study, iatrogenic hypothyroidism was com-
mon in RAI-treated cats: 22% of recruited cats were diagnosed
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with hypothyroidism, with a further 18% of cats in the RAI-equivo-
cal group demonstrating a subnormal response to rhTSH adminis-
tration. The high prevalence of elevated endogenous TSH in our
study (37%), alongside within-RI tT4 concentrations, supports the
conclusion of a previous study that “subclinical” hypothyroidism
appears to be common in RAI-treated cats.6 Despite the fact that
tT4 concentrations were within reference range in the majority of
our RAI-treated cats, clinically important effects on kidney func-
tion can be inferred due to the significantly higher serum creati-
nine and BUN concentrations and higher SBP in hypothyroid cats,
compared to the control group or euthyroid RAI-treated cats. Pre-
vious studies have demonstrated the link between increased risk
of azotemia and hypothyroidism in cats following RAI treat-
ment5,31 and a significant effect of untreated hypothyroidism on
the survival of RAI and medically treated cats with CKD.5,6 There-
fore, the identification and treatment of hypothyroidism has
important implications on the longevity of RAI-treated cats.
In our study, SBP was significantly higher in RAI-hypothyroid cats
compared to control cats. In humans, naturally occurring hypothyroid-
ism is associated with an increased prevalence of hypertension, with
treatment of hypothyroidism leading to a reduction in systolic and dia-
stolic blood pressure.32 The pathophysiological mechanism for hyper-
tension in hypothyroidism is unclear; however, it is postulated that
hypertension could be secondary to increased total peripheral resis-
tance, increased β-adrenergic responsiveness, or extracellular fluid
volume expansion.32 Therefore, the increased SBP observed in hypo-
thyroid cats in our study could reflect these pathophysiological
changes in cats with iatrogenic hypothyroidism. Treatment of hyper-
thyroidism is associated with the development of systolic hyperten-
sion in approximately 23% of initially normotensive hyperthyroid cats
(Morrow L, Adams VJ, Elliott J, Syme H. Hypertension in hyperthyroid
cats: prevalence, incidence and predictors of its development. J Vet
Int Med. 2009;23:700 (abstract)) however to date, no studies have
investigated if this correlates with the development of iatrogenic
hypothyroidism after treatment. In one previous study, total T4 was
not significantly different between treated hyperthyroid cats which
were hypertensive or normotensive after treatment; however, serum
TSH concentrations were not measured contemporaneously to
exclude low TT4 secondary to nonthyroidal illness.33
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